A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN SUBJECTS WITH ACTIVE ANKYLOSING SPONDYLITIS
Phase of Trial: Phase III
Latest Information Update: 23 Nov 2019
Price : $35 *
At a glance
- Drugs Bimekizumab (Primary)
- Indications Ankylosing spondylitis
- Focus Registrational; Therapeutic Use
- Acronyms BE MOBILE 2
- Sponsors UCB
- 24 May 2019 Status changed from not yet recruiting to recruiting.
- 02 Aug 2018 New trial record
- 26 Jul 2018 According to an UCB media release, the company is planning to start the trial by the end of 2018.